Genetic initiation, progression and prognostic markers in transitional cell carcinoma of the bladder: A summary of the structural and transcriptional changes, and the role of developmental genes

British Journal of Urology

Volumn 82, Issue 4, 1998, Pages 503-512

  Adshead, J M ^a   Kessling, A M ^a   Ogden, C W ^a  

^a IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

ANGIOGENESIS; APOPTOSIS; BLADDER CANCER; BLADDER CARCINOGENESIS; CHROMOSOME 11; CHROMOSOME 9; CHROMOSOME ABERRATION; CYTOGENETICS; EXTRACELLULAR MATRIX; GENE AMPLIFICATION; GENE STRUCTURE; GENETIC ANALYSIS; GENETIC TRANSCRIPTION; HETEROZYGOSITY LOSS; HUMAN; PLOIDY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TRANSITIONAL CELL CARCINOMA; TRISOMY; TUMOR SUPPRESSOR GENE;

APOPTOSIS; CARCINOMA, TRANSITIONAL CELL; CELL DIVISION; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 11; CHROMOSOMES, HUMAN, PAIR 9; DISEASE PROGRESSION; EXTRACELLULAR MATRIX; GENE AMPLIFICATION; GENE DELETION; GENES, P53; GENES, RETINOBLASTOMA; HUMANS; LOSS OF HETEROZYGOSITY; NEOVASCULARIZATION, PATHOLOGIC; PLOIDIES; PROGNOSIS; TRISOMY; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 0031721817     PISSN: 00071331     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-410X.1998.00767.x     Document Type: Review

References (109)

1. Thrasher JB, Crawford ED. Current management of invasive and metastatic transitional cell carcinoma of the bladder. J Ural 1993: 149: 957-972
2. Sobin LH. Flemming ID. TNM Classification of Malignant Tumors, 5th edn. Union Internationale Contre le Cancer and the American Joint Committee on Cancer. Cancer: 1997: 80: 1803-4
3. Soloway MS. Managing superficial bladder cancer: an overview. Urology 1992: 40: 11-22
4. Koontz WW. Heney NM, Soloway MS et al. Mitomycin for patients who have failed on thiotepa. The National Bladder Cancer Group. Urology 1985: 26 (suppl 4): 30-1
5. Chen SS. Chen KK, Lin AT et al. The significance of tumour grade in predicting disease progression in stage Ta transitional cell carcinoma of the urinary bladder. Br J Urol 1996: 78: 209-12
6. Stuart ET. Gruss P. PAX genes: what's new in developmental biology and cancer? Hum Mol Gen 1995: 4: 1717
7. Matsuyama H, Bergerheim US. Nilsson I et al. Nonrandom numerical aberrations of chromosomes 7, 9. and 10 in DNA-diploid bladder cancer. Cancer Genet Cytogenetics 1994: 77: 118-24
8. Hopman AH. van Hooren E. van de Kaa ÇA et al. Detection of numerical chromosome aberrations using in situ hybridization in paraffin sections of routinely processed bladder cancers. Modern Pathol 1991: 4: 503-13
9. Hopman AH, Moesker 0. Smeets AW, Pauwels RP. Vooijs GP, Ramaekers FC. Numerical chromosome 1. 7. 9. and 11 aberrations in bladder cancer detected by in situ hybridization. Cancer Res 1991: 51: 644-51
10. Waldman FM. Carroll PR. Kerschmann R. Cohen MB. Field FG. Mayall BH. Centromeric copy number of chromosome 7 is strongly correlated with tumor grade and labeling index in human bladder cancer. Cancer Res 1991; 51: 3807-13
11. Mitelman F, Mertens F, Johansson B. A breakpoint map of recurrent chromosomal rearrangements in human neoplasia. Nature Genetics 1997; Special issue 15: 417-74
12. Raitanen MP, Tammela TL, Kallioinen M, Isola J. P53 accumulation, deoxyribonucleic acid ploidy and progression of bladder cancer. / Urol 1997; 157:1250-3
13. Slaton JW, Dinney CP, Veltri RW et al. Deoxyribonucleic acid ploidy enhances the cytological prediction of recurrent transitional cell carcinoma of the bladder. / Urol 1997; 158: 806-11
14. Neulander E. Kaneti J, Chaimovitz C. Sion VN. Douvdevani A. Deoxyribonucleic acid ploidy and the clinical pattern of grade 2 superficial bladder cancer. / Urol 1997; 157: 1254-8
15. Yokogi H, Wada Y, Moriyama GN. Igawa M. Ishibe T. Genomic heterogeneity in bladder cancer as detected by fluorescence in situ hybridization. Br / Urol 1996; 78: 699-703
16. Knowles MA. Molecular genetics of bladder cancer. Br } Urol 1995; 1: 57-66
17. Reznikoff CA. Belair CD, Yeager TR et al. A molecular genetic model of human bladder cancer pathogenesis. Semin Oncol 1996; 23: 571-84
18. Tsai YC. Nichols PW, Hiti AL. Williams Z. Skinner DG, Jones PA. Allelic losses of chromosomes 9, 11, and 17 in human bladder cancer. Cancer Res 1990; 50: 44-7
19. Isobe M. Emmanuel BS, Givol D. Location of the gene for human p53 tumour antigen to band 17pl3. Nature 1986; 320: 84-5
20. Marx J. How p53 suppresses cell growth. Science 1993; 262: 1644-5
21. Donehower LA, Harvey M, Slagle BL et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 1992; 356: 215-21
22. Marshall CJ. p53 tumor suppressor genes. Cell 1991; 64: 313-26
23. Dalbagni G, Presti JJ. Reuter VE et al. Molecular genetic alterations of chromosome 17 and p53 nuclear overexpression in human bladder cancer. Diagnostic Mol Pathol 1993; 2: 4-13
24. Esrig D, Spruck C, Nichols PW et al. p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer. Am J Pathol 1993; 143: 1389-97
25. Tetu B, Allard P. Fradet Y. Roberge N. Bernard P. Prognostic significance of nuclear DNA content and S-phase fraction by flow cytometry in primary papillary superficial bladder cancer. Human Pathol 1996: 27: 922-6
26. Sarkis AS, Bajorin DF, Reuter VE et al. Prognostic value of p53 nuclear overexpression in patients with invasive bladder cancer treated with neoadjuvant MVAC. / Clin Oncol 1995; 13: 1384-90
27. Fujimoto K, Yamada Y, Okajima E et al. Frequent association of p53 gene mutation in invasive bladder cancer. Cancer Res 1992; 52: 1393-8
28. Miyamoto H. Shuin T, Ikeda I, Hosaka M, Kubota Y. Loss of heterozygosity at the p53, RB, DCC and APC tumor suppressor gene loci in human bladder cancer. J Urol 1996; 155: 1444-7
29. Watanabe R, Tomita Y, Nishiyama T, Tanikawa T, Sato S. Correlation of p53 protein expression in human urothelial transitional cell cancers with malignant potential and patient survival. Int J Urol 1994; 1: 43-8
30. Esrig D, Elmajian D. Groshen S et al. Accumulation of nuclear p53 and tumor progression in bladder cancer. New Eng J Med 1994; 331: 1259-64
31. Tsuji M, Kojima K, Murakami Y, Kanayama H, Kagawa S. Prognostic value of Ki-67 antigen and p53 protein in urinary bladder cancer: immunohistochemical analysis of radical cystectomy specimens. Br/ Urol 1997: 79: 367-72
32. Click SH, Howell LP. White RW. Relationship of p53 and bcl-2 to prognosis in muscle-invasive transitional cell carcinoma of the bladder. / Urol 1996; 155: 1754-7
33. Kuczyk MA, Bokemeyer C, Serth J et al. p53 overexpression as a prognostic factor for advanced stage bladder cancer. EurJ Cancer 1995; 31: 2243-7
34. Moch H, Sauter G, Mihatsch MJ, Gudat F, Epper R, Waldman FM. p53 but not erbB-2 expression is associated with rapid tumor proliferation in urinary bladder cancer. Human Pathol 1994; 25: 1346-51
35. Underwood MA, Reeves J, Smith G et al. Overexpression of p53 protein and its significance for recurrent progressive bladder tumours. Br J Urol 1996: 77: 659-66
36. Sarkis AS. Dalbagni G. Cordon CC et al. Association of P53 nuclear overexpression and tumor progression in carcinoma in situ of the bladder. / Urol 1994; 152: 388-92
37. Schmitz-Drager BJ, van Royen CR, Grimm MO et al. P53 accumulation in precursor lesions and early stages of bladder cancer. WorldJ Urol 1994; 12: 79-83
38. Hudson MA, Herr HW. Carcinoma in situ of the bladder. JUrol 1995; 153: 564-72
39. Cote RJ, Esrig D, Groshen S, Jones PA. Skinner DG. p53 and treatment of bladder cancer. Nature 1997; 385: 123-5
40. Löwe SW. Jacks T. Reply to letter. Nature 1997: 385: 123-5
41. Lee WH, Shew JY, Hong FD et al. The retinoblastoma susceptibility gene encodes a nuclear phosphoprotein associated with DNA binding activity. Nature 1987; 329; 642-5
42. Lees JA, Buchkovich KJ, Marshak DR, Anderson CW, Harlow E. The retinoblastoma protein is phosphorylated on multiple sites by human cdc2. EMBO / 1991: 10: 4279-90
43. Goodrich DW. Wang NP. Qian YW, Lee EY, Lee WH. The retinoblastoma gene product regulates progression through the Gl phase of the cell cycle. Cell 1991; 67: 293-302
44. Whyte P. Buchkovich KJ, Horowitz JM et al. Association between an oncogene and an anti-oncogene: the adenovirus El A proteins bind to the retinoblastoma gene product. Nature 1988; 334: 124-9
45. Xu HJ, Cairns P, Hu SX, Knowles MA, Benedict WF. Loss of RB protein expression in primary bladder cancer correlates with loss of heterozygosity at the RB locus and tumor progression. Int J Cancer 1993; 53: 781-4
46. Logothetis CJ, Xu HJ, Ro JY et al. Altered expression of retinoblastoma protein and known prognostic variables in locally advanced bladder cancer. / Nat) Cancer Inst 1992; 84: 1256-61
47. Cordon CC, Wartinger D, Petrylak D et al. Altered expression of the retinoblastoma gene product: prognostic indicator in bladder cancer. / NatI Cancer Inst 1992: 84: 1251-6
48. Presti JJ, Reuter VE. Galan T, Fair WR, Cordon CC. Molecular genetic alterations in superficial and locally advanced human bladder cancer. Cancer Res 1991: 51: 5405-9
49. Habuchi T, Ogawa 0, Kakehi Y et al. Accumulated allelic losses in the development of invasive urothelial cancer. Int J Cancer 1993: 53: 579-84
50. Miyamoto H. Shuin T. Torigoe S. Iwasaki Y, Kubota Y. Retinoblastoma gene mutations in primary human bladder cancer. ErJ Cancer 1995: 71: 831-5
51. Vanni R. Scarpa RM, Nieddu M. Usai E. Cytogenetic investigation on 30 bladder carcinomas. Cancer Genet Cytogenetics 1988; 30: 35-42
52. Gibas Z. Prout GJ, Connolly JG, Pontes JE, Sandberg AA. Nonrandom chromosomal changes in transitional cell carcinoma of the bladder. Cancer Res 1984: 44: 1257-64
53. Pycha A. Mian C. Haitel A. Hofbauer J. Wiener H. Marberger M. Fluorescence in situ hybridization identifies more aggressive types of primarily noninvasive (stage pTa) bladder cancer. / Urol 1997; 157: 2116-9
54. Cairns P. Shaw ME. Knowles MA. Preliminary mapping of the deleted region of chromosome 9 in bladder cancer. Cancer Res 1993; 53: 1230-2
55. Van Tilborg AA. Hekman AC. Vissers KJ et al. Loss of heterozygosity on chromosome 9 and loss of chromosome 9 copy number are separate events in the pathogenesis of transitional cell carcinoma of the bladder. Int J Cancer 1998: 75: 9-14
56. Povey S, Attwood J, Chadwick B et al. Report on the Fifth International Workshop on Chromosome 9 held at Eynsham. Oxfordshire. UK. September 4-6, 1996. Ann Human Genetics 1997; 61: 183-206
57. Stadier WM. Olopade 01. The 9p21 region in bladder cancer cell lines: large homozygous deletion inactivate the CDKN2. CDKN2B and MTAP genes. Urol Res 1996: 24: 239-44
58. Wu 0. Possati L, Montesl M et al Growth arrest and suppression of tumorigenicity of bladder-carcinoma cell lines induced by the P16/CDKN2 (pl6INK4A, MTS1) gene and other loci on human chromosome 9. Int J Cancer 1996: 65: 840-6
59. Fearon ER. Feinberg AP. Hamilton SH, Vogelstein B. Loss of genes on the short arm of chromosome 11 in bladder cancer. Nature 1985: 318: 377-80
60. Olumi AF. Tsai YC, Nichols PW et al. Allelic loss of chromosome 17p distinguishes high grade from low grade transitional cell carcinomas of the bladder. Cancer Res 1990; 50: 7081-3
61. Voorter CE. Ummelen MI. Ramaekers FS, Hopman AH. Loss of chromosome 11 and 11 p/q imbalances in bladder cancer detected by fluorescence in situ hybridization. Int J Cancer 1996; 65: 301-7
62. Li M. Zhang ZF, Reuter VE, Cordon CC. Chromosome 3 allelic losses and microsatellite alterations in transitional cell carcinoma of the urinary bladder. Am J Pathol 1996: 149: 229-35
63. Elder PA. Bell SM, Knowles MA. Deletion of two regions on chromosome 4 in bladder carcinoma: definition of a critical 750kB region at 4pl6.3. Oncogme 1994: 9: 3433-6
64. Polascik TJ. Cairns P. Chang WY. Schoenberg MP. Sidransky D. Distinct regions of allelic loss on chromosome 4 in human primary bladder carcinoma. Cancer Res 1995; 55: 5396-9
65. Bell SM. Zuo J. Myers RM. Knowles MA. Fluorescence in situ hybridization deletion mapping at 4pl6.3 in bladder cancer cell lines refines the localisation of the critical interval to 30kb. Genes, Chromosomes Cancer 1996: 17: 108-17
66. Knowles MA. Shaw ME. Proctor AJ. Deletion mapping of chromosome 8 in cancers of the urinary bladder using restriction fragment length polymorphisms and microsatellite polymorphisms. Oncogene 1993; 8: 1357-64
67. Wagner U. Bubendorf L. Gasser TC et al. Chromosome 8p deletions are associated with invasive tumor growth in urinary bladder cancer. Am J Pathol 1997; 151: 753-9
68. Steck PA, Pershouse MA, Jasser SA et al. Identification of a candidate tumour suppressor gene, MMAC1. at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nature Genet 1997; 15: 356-62
69. Mollenhauer J. Wiemann S. Scheurlen W et al. DMBT1, a new member of the SRCR superfamily. on chromosome 10q2 5.3-26.1 is deleted in malignant brain tumours. Nature Genet 1997; 17: 32-9
70. Cappellen D. Gil Diez de Medina S. Chopin D, Thiery JP. Radvanyi F. Frequent loss of heterozygosity on chromosome lOq in muscle-invasive transitional cell carcinomas of the bladder. Oncogene 1997: 14: 3059-66
71. Brewster SF. Gingell JC. Browne S, Brown KW. Loss of heterozygosity on chromosome 18q is associated with muscle-invasive transitional cell carcinoma of the bladder. Br J Cancer 1994: 70: 697-700
72. Strohmeyer TG. Proto-oncogenes and tumour supressor genes in human urological malignancies. J Urol 1994; 151: 1479-97
73. Proctor AJ. Coombs LM, Cairns JP, Knowles MA. Amplification at chromosome Ilql3 in transitional cell tumours of the bladder. Oncogene 1991: 6: 789-95
74. Bringuier PP. Tamimi J, Schurring E, Schalken J. Expression of cyclin Dl and EMS1 in bladder tumours: relationship with chromosome Ilql3 amplification. Oncogene 1996; 12: 1747-53
75. Savelieva E. Belair CD. Newton MA et al. 20q gain associates with immortalization: 20ql3.2 amplification correlates with genome instability in human papillomavirus 16. E7 transformed human uroepithelial cells. Oncogene 1997: 14: 551-60
76. Bargmann C. Hung MC, Weinberg RA. The Neu oncogene encodes an epidermal growth factor receptor-related protein. Nature 1986; 319: 226
77. Slamon DJ, Godolphin W. Jones LA et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244: 707-12
78. Sauter G, Moch H, Moore D et al. Heterogeneity of erbB-2 gene amplification in bladder cancer. Cancer Res 1993; 53: 2199-203
79. Coombs LM. Pigott DA, Sweeney E et al. Amplification and over-expression of c-erbB-2 in transitional cell carcinoma of the urinary bladder. Br / Cancer 1991; 63: 601-8
80. Mellon JK, Lunée J. Wright C, Home CH, Kelly P, Neal DE. C-erbB-2 in bladder cancer: molecular biology, correlation with epidermal growth factor receptors and prognostic value. / Vrol 1996: 155: 321-6
81. Berrozpe G, Miro R, Caballin MR, Salvador J, Egozcue J. Trisomy 7 may be a primary change in noninvasive transitional cell carcinoma of the bladder. Cancer Genet Cytogenetics 1990; 50: 9-14
82. Der CJ, Krontitis T. Cooper GM. Transforming genes of human bladder and lung carcinoma cell lines are homologous to the ras genes of Harvey and Kirsten sarcoma viruses. Proc Natl Acad Sei 1982; 79: 3637-40
83. Fontana D, Bellina M, Scoffone C et al. Evaluation of c-ras oncogene product (p21) in superficial bladder cancer. Eur Urol 1996: 29: 470-6
84. Hong SJ, Lee T, Park YS, Lee KO, Chung BH, Lee SH. A PCR-RFLP method for the detection of activated H-ras oncogene with a point mutation at codon 12 and 61. Yonsei Med J 1996; 37: 371-9
85. Saito S, Hata M, Fukuyama R et al. Screening of H-ras gene point mutations in 50 cases of bladder carcinoma. M }Urol 1997; 4: 178-85
86. Vageli D, Kiaris H, Delakas D, Anezinis P, Cranidis A, Spandidos DA. Transcriptional activation of H-ras. K-ras and N-ras proto-oncogenes in human bladder tumors. Cancer Lett 1996: 107: 241-7
87. Folkman J. Anti-angiogenesis: new concept for therapy of solid tumours. Ann Surg 1972; 175: 409-16
88. Lipponen PK. Expression of cathepsin D in transitional cell bladder tumours. / Pathol 1996; 178: 59-64
89. Hasui Y, Marutsuka K, Asada Y, Osada Y. Prognostic value of urokinase-type plasminogen activator in patients with superficial bladder cancer. Urology 1996; 47: 34-7
90. Gohji K, Fujimoto N. Fujii A. Komiyama T, Okawa J, Nakajima M. Prognostic significance of circulating matrix metalloproteinase-2 to tissue inhibitor of metalloproteinases-2 ratio in recurrence of urothelial cancer after complete resection. Cancer Res 1996; 56: 3196-8
91. Davies B, Waxman J. Wasan H et al. Levels of matrix metalloproteases in bladder cancer correlate with tumor grade and invasion. Cancer Res 1993; 53: 5365-9
92. Polverini PJ. The pathophysiology of angiogenesis. Crit Rev Oral Biol Med 1995; 6: 230-47
93. Bochner BH, Cote RJ, Weidner N et al. Angiogenesis in bladder cancer: relationship between microvessel density and tumor prognosis. / Natl Cancer Inst 1995; 87: 1603-12
94. Dickinson AJ. Fox SB, Persad RA, Hollyer J, Sibley GN, Harris AL. Quantification of angiogenesis as an indepen-dent predictor of prognosis in invasive bladder carcinomas. BrJ Urol 1994; 74: 762-6
95. O'Brien T, Cranston D, Fuggle S, Bicknell R, Harris AL. Different angiogenic pathways characterize superficial and invasive bladder cancer. Cancer Res 1995; 55: 510-3
96. O'Reilly MS, Holmgren L, Chen C, Folkman J. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nature Med 1996; 2: 689-92
97. Holmgren L, O'Reilly MS, Folkman J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nature Med 1995; 1: 149-53
98. Rak J, Filmus J, Finkenzeller G, Grugel S, Marme D. Kerbel RS. Oncogenes as inducers of tumor angiogenesis. Cancer Metastasis Rev 1995; 14: 263-77
99. Volpert 0V, Dameron KM, Bouck N. Sequential development of an angiogenic phenotype by human fibroblasts progressing to tumorigenicity. Oncogene 1997: 14: 1495-502
100. Maulbecker CC, Gruss P. The oncogenic potential of Pax genes. EMBO / 1993; 12: 2361-7
101. Baumgartner S, Bopp D, Burri M, Noll M. Structure of two genes of the gooseberry locus related to the paired gene and their spatial expression during Drosphilia embryogenesis. Genes Dev 1987: 1: 1247-67
102. Stuart ET, Kioussi C, Gruss P. Mammalian Pax genes. Annu Rev Genet 1994; 28: 219-36
103. Gnarra JR, Dressler GR. Expression of Pax-2 in human renal cell carcinoma and growth inhibition by antisense oligonucleotides. Cancer Res 1995; 55: 4092-8
104. Stuart ET, Kioussi C, Aguzzi A, Gruss P. PAX5 expression correlates with increasing malignancy in human astrocytomas. Clin Cancer Res 1995; 1: 207-14
105. Stuart ET, Haffner R, Oren M, Gruss P. Loss of p53 function through PAX-mediated transcriptional repression. EMBOJ 1995; 14: 5638-45
106. Gazzaniga P, Gradilone A, Vercillo R et al. Bcl-2/bax mRNA expression ratio as prognostic factor in low-grade urinary bladder cancer. Int} Cancer 1996; 69: 100-4
107. Blasco-Olaetxea E, Belloso L, Garcia-Tamayo J. Superficial bladder cancer: study of the proliferative nuclear fraction as a prognostic factor. Bur / Cancer 1996; 32A: 444-6
108. Jones HL. Delahunt B. Bethwaite PB, Thornton A. Polyclonal Ki-67 expression in transitional cell carcinoma of the bladder. Pathology 1997; 29: 84-7
109. Kamata S. Kageyama Y, Yonese J, Oshima H. Significant telomere reduction in superficial transitional carcinoma. BrJ Urol 1995; 78: 704-8